Tinya J. Abrams

5.2k total citations · 2 hit papers
17 papers, 2.1k citations indexed

About

Tinya J. Abrams is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Tinya J. Abrams has authored 17 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Hematology. Recurrent topics in Tinya J. Abrams's work include HER2/EGFR in Cancer Research (6 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Cancer Cells and Metastasis (3 papers). Tinya J. Abrams is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Cancer Cells and Metastasis (3 papers). Tinya J. Abrams collaborates with scholars based in United States, Switzerland and Australia. Tinya J. Abrams's co-authors include Lesley Murray, Julie M. Cherrington, Leslie B. Lee, Nancy Pryer, Michael C. Heinrich, William C. Manning, Sharianne G. Louie, Beverly D. Smolich, Ajia Town and Kevin Yee and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Tinya J. Abrams

17 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

2003 703 citations Tinya J. Abrams, Sharianne G. Louie et al. Blood profile →
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

2003 549 citations Tinya J. Abrams, Leslie B. Lee et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tinya J. Abrams United States	12	936	835	824	415	322	17	2.1k
Leslie B. Lee United States	13	1.0k 1.1×	790 0.9×	988 1.2×	391 0.9×	325 1.0×	13	2.3k
Nicoletta Brega United States	16	995 1.1×	825 1.0×	804 1.0×	601 1.4×	301 0.9×	52	2.1k
Andreas H. Marx Germany	26	698 0.7×	1.3k 1.5×	822 1.0×	170 0.4×	301 0.9×	75	2.2k
Sharianne G. Louie United States	11	1.0k 1.1×	581 0.7×	514 0.6×	859 2.1×	299 0.9×	12	2.0k
Heike Richly Germany	20	1.1k 1.1×	1.2k 1.4×	736 0.9×	184 0.4×	380 1.2×	56	2.4k
Sophia Abraham United States	8	832 0.9×	569 0.7×	491 0.6×	224 0.5×	201 0.6×	12	1.6k
Lorenzo Gianni Italy	21	405 0.4×	1.2k 1.4×	526 0.6×	181 0.4×	600 1.9×	91	2.0k
Laurie Sherman United States	15	1.2k 1.3×	1.0k 1.3×	474 0.6×	176 0.4×	188 0.6×	41	1.9k
María Alsina Spain	22	595 0.6×	1.3k 1.6×	1.3k 1.6×	88 0.2×	286 0.9×	109	2.5k
Blair Marshall United States	9	795 0.8×	630 0.8×	514 0.6×	67 0.2×	487 1.5×	10	1.7k

Countries citing papers authored by Tinya J. Abrams

Since Specialization

Citations

This map shows the geographic impact of Tinya J. Abrams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tinya J. Abrams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tinya J. Abrams more than expected).

Fields of papers citing papers by Tinya J. Abrams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tinya J. Abrams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tinya J. Abrams. The network helps show where Tinya J. Abrams may publish in the future.

Co-authorship network of co-authors of Tinya J. Abrams

This figure shows the co-authorship network connecting the top 25 collaborators of Tinya J. Abrams. A scholar is included among the top collaborators of Tinya J. Abrams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tinya J. Abrams. Tinya J. Abrams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Tam, Angela, Katherine Seiss, Siqi Liu, et al.. (2019). Abstract 4743: Using genome-wide CRISPR screen to understand resistance mechanisms to PCA062, a P-cadherin targeting antibody-drug conjugate. Cancer Research. 79(13_Supplement). 4743–4743. 1 indexed citations

Orozco, Olivia, Tinya J. Abrams, Jayesh Desai, et al.. (2018). Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies. Clinical Cancer Research. 24(14). 3465–3474. 18 indexed citations

Karpov, Alexei S., Tinya J. Abrams, Joseph A. D’Alessio, et al.. (2018). Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody–Drug Conjugates. ACS Medicinal Chemistry Letters. 9(8). 838–842. 29 indexed citations

Abrams, Tinya J., Xiaohong Niu, Millicent Embry, et al.. (2015). Abstract 1695: Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML. Cancer Research. 75(15_Supplement). 1695–1695. 2 indexed citations

Menezes, Daniel L., Tinya J. Abrams, Yan Tang, et al.. (2015). Abstract 1682: Development and activity of a novel antibody-drug conjugate for the treatment of P-cadherin expressing cancers. Cancer Research. 75(15_Supplement). 1682–1682. 8 indexed citations

Schnell, Christian, et al.. (2013). Abstract 3370: Use of fine needle aspirate biopsy (FNAB) in evaluating drug responses in tumor models: Better data with less animal use? .. Cancer Research. 73(8_Supplement). 3370–3370. 1 indexed citations

Menezes, Daniel L., Pietro Taverna, Michael Rugaard Jensen, et al.. (2012). The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo. Molecular Cancer Therapeutics. 11(3). 730–739. 57 indexed citations

Damiano, Jason S., Katherine G. Rendahl, Millicent Embry, et al.. (2012). Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer. Molecular Cancer Therapeutics. 12(3). 295–305. 49 indexed citations

Guagnano, Vito, Diana Graus Porta, Vincent Bordas, et al.. (2011). Abstract B246: NVP-BGJ398: A potent and selective inhibitor of the fibroblast growth factor receptor family.. Molecular Cancer Therapeutics. 10(11_Supplement). B246–B246. 1 indexed citations

10.

Xin, Xiaohua, Tinya J. Abrams, Paul W. Hollenbach, et al.. (2006). CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice. Clinical Cancer Research. 12(16). 4908–4915. 53 indexed citations

11.

Marzola, Pasquina, Anna Degrassi, Laura Calderan, et al.. (2004). In Vivo Assessment of Antiangiogenic Activity of SU6668 in an Experimental Colon Carcinoma Model. Clinical Cancer Research. 10(2). 739–750. 62 indexed citations

12.

Abrams, Tinya J., Lesley Murray, Enrico Pesenti, et al.. (2003). Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.. PubMed. 2(10). 1011–21. 215 indexed citations

13.

Murray, Lesley, Tinya J. Abrams, Lisa Olson, et al.. (2003). SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clinical & Experimental Metastasis. 20(8). 757–766. 254 indexed citations

14.

Abrams, Tinya J., Sharianne G. Louie, Kevin Yee, et al.. (2003). SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 101(9). 3597–3605. 703 indexed citations breakdown →

15.

Abrams, Tinya J., Leslie B. Lee, Lesley Murray, Nancy Pryer, & Julie M. Cherrington. (2003). SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.. PubMed. 2(5). 471–8. 549 indexed citations breakdown →

16.

Sohal, Jastinder, Vernon T. Phan, Elizabeth M. Davis, et al.. (2003). A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood. 101(8). 3188–3197. 84 indexed citations

17.

Abrams, Tinya J., Raphael C. Guzman, Steven M. Swanson, et al.. (1999). Changes in the parous rat mammary gland environment are involved in parity-associated protection against mammary carcinogenesis.. PubMed. 18(6A). 4115–21. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact